Exelixis, Inc. (Nasdaq:EXEL) will release its second quarter 2009
financial results on Thursday, July 30, 2009 after the markets close.
The announcement will be followed by a live webcast at 5:00 p.m. EDT/
2:00 p.m. PDT, in which Exelixis management will discuss the results and
provide a general business update. The webcast may be accessed in the
Event Calendar page under Investors at www.exelixis.com.
An audio replay of the webcast will be available until 11:59 p.m EDT/
8:59 p.m. PDT on August 30, 2009. Access numbers for the replay are:
1-888-286-8010 (domestic) and 1-617-801-6888, and the passcode is
72259030.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to
the discovery and development of novel small molecule therapeutics for
the treatment of cancer and other serious diseases. The company is
leveraging its fully integrated drug discovery platform to fuel the
growth of its development pipeline, which is primarily focused on
cancer. Currently, Exelixis’ broad product pipeline includes
investigational compounds in phase 3, phase 2, and phase 1 clinical
development. Exelixis has established strategic corporate alliances with
major pharmaceutical and biotechnology companies, including
Bristol-Myers Squibb, sanofi-aventis, GlaxoSmithKline, Genentech,
Boehringer Ingelheim, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For
more information, please visit the company’s web site at www.exelixis.com.
Exelixis, Inc.
Investor Contact:
Charles
Butler, 650-837-7277
Executive Director,
Corporate
Communications
cbutler@exelixis.com
Media
Contact:
Soleil Maxwell Harrison, 650-837-7012
Senior
Manager,
Corporate Communications
sharrison@exelixis.com
